According to a BHU study on the long-term effects of Bharat Biotech’s Covaxin vaccination, approximately one-third of those who got the anti-COVID vaccine had ‘adverse events of special interest,’ or AESI.
Almost one-third of the 926 individuals who underwent the study’s examination reported having an AESI, with viral upper respiratory tract infections being the most common complaint.
In one per cent of individuals, serious AESI including stroke and Guillain-Barre syndrome were reported.
The research, which was conducted from January 2022 to August 2023, included 635 adolescents and 291 adults who got the Covaxin vaccination. The research, which was conducted from January 2022 to August 2023, included 635 adolescents and 291 adults who got the Covaxin vaccination. Skin and subcutaneous problems, general disorders and nervous system disorders were among the most often observed AESI in teenagers. In adults, general disorders, musculoskeletal problems and nervous system disorders were common.
The study found that females, teenagers with pre-vaccination Covid-19, individuals with underlying health issues, and those who had typhoid after vaccination had 1.6, 2, 2.7, and 3.2 times increased probabilities of persistent AESIs.
The study also found that persons with pre-existing health conditions were more than double as likely to have AESIs and persistent AESIs.
Adults who got three doses of vaccination and just one dose of BBV152 were four and two times more likely to get AESIs than those who received two doses of Covaxin, according to the research.